Table 1.
Dose and Modification Guidelines for Lenalidomide in Patients With Renal Insufficiency
| DEGREE OF RENAL IMPAIRMENT | RENAL FUNCTION (COCKCROFT-GAULT) | MODIFIED DOSE FOR MULTIPLE MYELOMA |
|---|---|---|
| Moderate | CLcr 30–60a ml per minute | 10 mg every 24 hours |
| Severe (not requiring dialysis) | CLcr less than 30 ml per minute | 15 mg every 48 hours |
| End-stage renal disease (requiring dialysis) | CLcr less than 30 ml per minute | 5 mg once daily. On days of dialysis, the dose should be administered following dialysis. |
a
The definition of moderate renal impairment in the prescribing information approved by the European Medicines Agency for use in the European Union is 30 ≤ CLcr < 50 ml per minute.
CLcr—creatinine clearance
Note. The normal CLcr range for men is 97–137 ml per minute and 88–128 ml per minute for women.
Note. Based on information from Celgene Corp., 2010a.